<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992420</url>
  </required_header>
  <id_info>
    <org_study_id>P95082S</org_study_id>
    <nct_id>NCT00992420</nct_id>
  </id_info>
  <brief_title>Genotype Information and Functional Testing Study</brief_title>
  <acronym>GIFT</acronym>
  <official_title>GIFT: Genotype Information and Functional Testing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accumetrics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The
      purpose of this study is to assess which genes influence residual platelet reactivity on
      standard dose clopidogrel therapy, and also to determine whether certain genes influence the
      incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in
      patients who have high residual platelet reactivity on standard dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>residual platelet reactivity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>GRAVITAS Study Arm A</arm_group_label>
    <description>&quot;Tailored&quot; clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRAVITAS Study Arm B</arm_group_label>
    <description>&quot;Standard&quot; clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GRAVITAS Study Arm C</arm_group_label>
    <description>Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for
        VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS
        randomization/selection determination.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling
             for VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS
             randomization/selection determination

        Exclusion Criteria:

          -  See GRAVITAS trial (ClinicalTrials.gov identifier: NCT00645918)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic, La Jolla, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Genomic Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>January 13, 2011</last_update_submitted>
  <last_update_submitted_qc>January 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Matthew Price, M.D./Principal Investigator</name_title>
    <organization>Scripps Health/Scripps Genomic Institute</organization>
  </responsible_party>
  <keyword>thienopyridine</keyword>
  <keyword>platelets</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>platelet function tests</keyword>
  <keyword>platelet</keyword>
  <keyword>genes</keyword>
  <keyword>cytochrome P450</keyword>
  <keyword>single nucleotide polymorphisms</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

